Recent Updates
Recently added Catalysts
FATE

Preliminary Phase 1 Results of a MICA/B-targeted CAR T cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy

Monday, June 1, 2026 1 min read
Key Takeaway: The article discusses preliminary Phase 1 results of a CAR T cell therapy targeting MICA/B, designed to address solid tumor escape mechanisms without the need for conditioning chemotherapy. However, the article lacks specific details on the results or implications of the study.
Price reaction · baseline $2.84 (2026-05-29 close) · hit pre-market · 5 other FATE headline(s) in the window, move may be shared
day 0 close · peak
-3.5%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Tags: FATE Viatris Investor Conferences Healthcare CAR T cell therapy solid tumors Phase 1 results MICA/B
Last updated: Jun 1, 2026

Biotech snapshot

Cash runway
$175M liquidity · $10M/mo burn
~15 mo
Low dilution risk
Lead asset
FT825Phase 1
Advanced Solid Tumor →

Catalyst track record

+215%
best trade around FATE's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for FATE.

See every catalyst's timing & PoA →